# US 2025/0127876 A1 · Porcine reproductive and respiratory syndrome vaccine virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0127876 A1
- Document ID: US20250127876A1
- Status: Published application
- Kind: A1
- Application number: 19/004,639
- Filed: 2024-12-30
- Published: 2025-04-24
- Earliest claimed: 2019-08-29
- Assignees: Elanco US Inc.; Elanco UK AH Limited
- Applicants: Elanco US Inc.; Elanco UK AH Limited
- Inventors: Stephen Qitu WU; Cinta Prieto SUAREZ; Geoffrey Gregory LABARQUE
- Web page: https://patentgrep.com/patent/US20250127876A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/525: {Virus}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2770/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.

## Claims

### Claim 1

A modified, live Porcine Reproductive and Respiratory Syndrome (PRRS) virus strain, wherein the consensus complementary DNA sequence of said PRRS strain is at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.

### Claim 2 (depends on 1)

The modified, live PRRS virus strain of claim 1, wherein the consensus complementary DNA sequence of said PRRS strain is at least 98% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.

### Claim 3 (depends on 1)

The modified, live PRRS virus strain of claim 1, wherein said PRRS strain is a DE 14-3073 strain designated PTA-125490; an ES 13-49 strain designated PTA-125489; an IT 14-32 strain designated PTA-125488, or a PL 14-02 strain designated PTA-125487.

### Claim 4 (depends on 1)

The modified, live PRRS virus strain of claim 1, wherein said PRRS virus strain is passaged at least 85 times in tissue culture cells.

### Claim 5

An immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent.

### Claim 6

A method of treating or preventing a symptom of Porcine Reproductive and Respiratory Syndrome (PRRS) in a porcine animal, comprising administering to said porcine animal an immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 98% identical to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.

### Claim 7 (depends on 6)

The method of treating of claim 6, wherein the symptom of PRRS is caused by a PRRS virus infection in a porcine animal.
